Bio-Synthesis
Private Company
Funding information not available
Overview
Founded in 1984, Bio-Synthesis is a private, revenue-generating contract research organization (CRO) providing critical synthetic biology services to the global life sciences industry. The company operates on a pure services business model, offering custom manufacturing of oligonucleotides, peptides, and antibodies, with a strong focus on advanced modifications and bioconjugation for therapeutic and diagnostic applications. While not developing its own therapeutics, Bio-Synthesis serves as a key enabler for biotech and pharma companies, particularly in the burgeoning fields of antisense oligonucleotides, RNA therapeutics, and targeted drug conjugates. Its longevity and broad service portfolio position it as a stable partner in a high-growth market.
Technology Platform
Integrated suite of solid-phase synthesis, modification, and bioconjugation chemistries for oligonucleotides (DNA, RNA, BNA, PNA, Morpholinos) and peptides, with specialties in ultra-long sequence synthesis, circular oligo synthesis, and biomolecular conjugation.
Opportunities
Risk Factors
Competitive Landscape
Operates in a crowded CRO/CMO space for basic oligo and peptide synthesis, competing with giants like Thermo Fisher and Eurofins. Its competitive advantage lies in niche, high-complexity services like ultra-long synthesis, extensive modifications, and complex bioconjugations, where fewer players have deep expertise.